Read more »
Friday, October 5, 2012
Circassia Initiates Pivotal Phase 3 ToleroMune® Trial In Cat Allergen-Induced Rhinoconjunctivitis
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, has announced the start of a pivotal phase 3 trial of its investigational ToleroMune(R) cat allergy treatment for cat allergen-induced rhinoconjunctivitis...
Read more »
Read more »
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment